Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)

NCT04482309 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04482309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04482309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 18, 2020
Completion date
March 23, 2027
Enrollment
477 (actual)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

part 1: bladder, biliary tract, cervical, endometrial, ovarian, pancreatic cancer, rare tumors, any tumor type excluding breast, gastric, colorectal cancer, part 2: her2 expressing/amplified solid tumors excluding breast, gastric, colorectal cancer